Cytarabine

Catalog No.S1648

Cytarabine Chemical Structure

Molecular Weight(MW): 243.22

Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

Size Price Stock Quantity  
USD 97 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Viability and CI vs Fa after 24-h exposure to cytarabine alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM (500 ng/ml for cytarabine; quadruplicates±s.e.m.).

    Leukemia, 2015, 29(8): 1702–1712. Cytarabine purchased from Selleck.

    Cell cycle was analyzed using propidium iodide (PI) staining and flow cytometry. The plots show PI staining at the x-axis and cell counts at the y-axis. The graphs were prepared using ModFit LT™ software (Verity Software House). Nd: not detected, Ara-c:Cytarabine

    J Exp Clin Cancer Res, 2017, 36(1):22. Cytarabine purchased from Selleck.

  • Flow cytometry analysis for cell surface expression of CD11b shows time- and dose-dependent upregulation of the marker CD11b in MLL-rearranged leukemia cells treated with EPZ-5676 and Cytarabine(Ara-C) as single agents and in combination.

    J Pharmacol Exp Ther, 2014, 350(3): 646-56. Cytarabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.
Features The 1st of a series of cancer drugs that alters the sugar component of nucleosides.
Targets
DNA synthesis [1]
(CCRF-CEM cells)
16 nM
In vitro

Cytarabine (AraC) is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM. [1] Increasing concentrations of Cytarabine (IC50 of 0.69 μM) results in decreased metabolic activity of sensitive rat leukemic cell line RO/1, and the cell toxity can be highly enhanced by transfection with human wt dCK (IC50 of 0.037 μM) but not the inactive, alternatively spliced dCK forms. [2] Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse L1210 cells MWXDfZRwfG:6aXRCpIF{e2G7 NEH0b5E{KGSjeYO= NXi4fW1FS3m2b4TvfIlkcXS7IHHnZYlve3RiZHXvfJlvfWOuZX;zbYRmKGGwYXzv[5VmNXOnboPpeIl3\SCvb4Xz[UBNOTJzMDDj[YxteyCjZoTldkA{KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvPCCwTT6= NFK4UZgyQTZ5NEmwNy=>
human CCRF-CEM cells MmK5R5l1d3SxeHnjxsBie3OjeR?= NV;WdlFVOyCmYYnz Mlu4R5l1d3SxeHnjbZR6KGGpYXnud5Qh\GWxeInueYNt\W:|aXTlJIFv[WyxZ4XlMZNmdnOrdHn2[UBpfW2jbjDDR3JHNUOHTTDj[YxteyCjZoTldkA{KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEhdk1w MXmxPVY4PDlyMx?=
human MCF7 cells MnLhR5l1d3SxeHnjxsBie3OjeR?= NF:xU2c{KGSjeYO= MnziR5l1d3SxeHnjbZR6KGGpYXnud5Qh\GWxeInueYNt\W:|aXTlJIFv[WyxZ4XlMZNmdnOrdHn2[UBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;NDDuUU4> MkX4NVk3PzR7MEO=
CCRF-CEM cell line NEnU[FFHfW6ldHnvckBie3OjeR?= NGfvUItKdmirYnn0JJRp\SC{ZYDsbYNifGmxbjDv[kBES1KILVPFUUBk\WyuIHzpcoUhcW5idnn0do8tKEWGNUC9OUBvVS5? M4XGcFE6QTV6OUS=
human P12-ICHIKAWA cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGfnSoxKdmirYnn0bY9vKG:oIHj1cYFvKFBzMj3JR2hKU0GZQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOVQhdk1w MonlV2FPT0WU
human CCRF-CEM cells MUXDfZRwfG:6aXRCpIF{e2G7 M1vMUlQ5KGh? NHzJflhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBES1KILVPFUUBk\WyuczDh[pRmeiB2ODDodpMh[nliY3XscEB1cXSncj3icJVmKGG|c3H5MEBGSzVyPUWuOlEhdk1w NHHxSFMyQTd2M{i1PC=>
CCRF-CEM cell lines M3HFeWZ2dmO2aX;uJIF{e2G7 NHXWOmE4OiCq MWDDc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRicnXwcIlk[XSrb36gc4YhS0OURj3DSW0h[2WubDDsbY5meyCkeTC1NEUh[W[2ZYKgO|IhcHJiaX7jeYJifGmxbjygSWQ2OD14IH7NMi=> NUHzUlk4OTZ3MkCyOC=>
human CCRF-CEM cells M37BWWN6fG:2b4jpZ:Kh[XO|YYm= NV\1fJd2PDhiaB?= MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDR3JHNUOHTTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkh[2WubITpeIVzNWKudXWgZZN{[XluIFnDOVA:PiCwTT6= NV;ZVoFxOjJ3OEK5PVE>
human SF268 cells NHTQenNEgXSxdH;4bYPDqGG|c3H5 NI\qSFJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUTjJ4ODDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;Nz62PEBvVS5? M3PpN|E6OzR3NUix
MOLT-4 human leukemic lymphoblastoid cell lines MonTR5l1d3SxeHnjxsBie3OjeR?= NX3oZWRuS3m2b4TvfIlkcXS7IHHnZYlve3RiTV;MWE01KGi3bXHuJIxmfWunbXnjJIx6dXCqb3LsZZN1d2mmIHPlcIwhdGmwZYOsJGlEPTB;MUCgcm0v NF7jS|k3QDJ5NUS2
human 697 cell NH\KOWFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWHJcohq[mm2aX;uJI9nKGi3bXHuJFY6PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFyLk[gcm0v NXXWR41ZW0GQR1XS
human ES1 cell M1\5S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2PvZ2lvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUKuPVchdk1w M4XQR3NCVkeHUh?=
CCRF-CEM human leukemic lymphoblastoid cell lines MnKyR5l1d3SxeHnjxsBie3OjeR?= NVHjeG9SS3m2b4TvfIlkcXS7IHHnZYlve3RiQ1PSSk1ETU1iaIXtZY4hdGW3a3XtbYMhdHmvcHjvZoxie3SxaXSgZ4VtdCCuaX7ld{whUUN3ME2yNEBvVS5? NYnCc|RUPjh{N{W0Oi=>
P388 murine cell lines Mk\GSpVv[3Srb36gZZN{[Xl? MYC3NkBp NFL2UVVVcGViY3;tdI92dmRid3HzJJRme3SnZDDpckB3cXS{bzDmc5Ih[W62aYT1cY9zKGGldHn2bZR6MDVyJTDpcohq[mm2aX;uJI9nKHS3bX;yJINmdGxiZ4Lve5RpMSCjZ3HpcpN1KHSqZTDQN|g5KG23cnnu[UBk\WyuIHzpcoV{KGGodHXyJFczKGixdYLzMEBKTDVyPUKwJI5ONg>? NFO5[nU{PjJ3N{G0
L1210 murine cell lines MXfGeY5kfGmxbjDhd5NigQ>? NH;afHg4OiCq NWLH[G9XXGinIHPvcZBwfW6mIIfhd{B1\XO2ZXSgbY4hfmm2cn:g[o9zKGGwdHn0eY1weiCjY4Tpeol1gSh3MDWgbY5pcWKrdHnvckBw\iC2dX3vdkBk\WyuIHfyc5d1cCliYXfhbY5{fCC2aHWgUFEzOTBibYXybY5mKGOnbHygcIlv\XNiYX\0[ZIhPzJiaH;1dpMtKEmGNUC9NlAhdk1w Ml3pN|YzPTdzNB?=
human HEL cell NHj5ZZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NInqd3pKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKwMlUzKG6PLh?= M1\OZ3NCVkeHUh?=
human CCRF-CEM/C2 cells M17IPWN6fG:2b4jpZ:Kh[XO|YYm= NIfyPJI1QCCq M4\YUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNEWkZvQ1XNM2MzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDj[YxtKHSrdHXyMYJtfWViYYPzZZktKEWFNUC9NlIvQCCwTT6= Mk\GNVk4PDN6NUi=
mouse L1210 cells MlfxR5l1d3SxeHnjxsBie3OjeR?= M3u3O|Q5KGh? NH;hd3VEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBNOTJzMDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA1QCCqcoOsJGlEPTB;MD6wNlQh|ryPLh?= NGDxSYEzODByMESxPC=>
human CEM cells M1nEWmN6fG:2b4jpZ:Kh[XO|YYm= MXS0PEBp MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDSW0h[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiNEigbJJ{NCCLQ{WwQVAvODJ2IN88UU4> NFjxUZIzODByMESxPC=>
human 2209-23 cells NVu2V2hQWHKxbHnm[ZJifGmxbjDhd5NigQ>? MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKDJ{MEmtNlMh[2WubIOgZpkhYzOKXYTofY1q\GmwZTDpcoNwenCxcnH0bY9vKHOlaX70bYxt[XSrb36gdJJwgGmvaYT5JIF{e2G7LDDJR|UxRTBwMEK5JO69VQ>? NUC2XWZ2OTlyNUW0PFI>
human CHP-212 cell NHrxU2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkfBTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|MvPDdibl2u MY\TRW5ITVJ?
human CTB-1 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1HSO2lvcGmkaYTpc44hd2ZiaIXtZY4hS1SELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOE4{KG6P NHzMXGJUSU6JRWK=
human A427 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoW1TY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{SuOFkhdk1w M4rrZ3NCVkeHUh?=
human MOLT-16 cell NUPtclR3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2jRNGlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM3NjB5IH7NMi=> MYDTRW5ITVJ?
human MCF7 1K cells NGm0WGNEgXSxdH;4bYPDqGG|c3H5 MofnN{Bl[Xm| MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBl\W:6eX71Z4xmd3OrZHWgZY5idG:pdXWtdoV{cXO2YX70JIh2dWGwIF3DSlchOUtiY3XscJMhd3[ncnX4dJJme3Orbnegdoljd263Y3zlc5Rq\GVicnXkeYN1[XOnIHHmeIVzKDNiZHH5d{BjgSCPVGSgZZN{[XluIFnDOVA:PDBibl2u NWTvSo9lOTl4N{S5NFM>
human MC-IXC cell M3HXOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYTJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSxMlQyKG6PLh?= NGPlZ25USU6JRWK=
human BHT-101 cell M3zrPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIL5cW1KdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01OS55NjDuUS=> MlHWV2FPT0WU
human K5 cell MkLVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDNwMjDuUS=> MlHCV2FPT0WU
parent promyelocytic leukemia cell line NFHBUIRHfW6ldHnvckBie3OjeR?= MV;BcpRq[2GwY3XyJIFkfGm4aYT5JJdieyCndnHseYF1\WRiZn;yJJRp\SClb33wc5Vv\CCjZ3HpcpN1KHCjcnXueEBxem:veXXsc4N6fGmlIHzleYtmdWmjIHPlcIwhdGmwZTCoTGwuPjBvR1jQVnQsN2SFSzupMEBGTDVyPUS3JI5ONg>? Ml7ON|AzPzN{OR?=
human HL60 cells MXzDfZRwfG:6aXRCpIF{e2G7 NEDsTXREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBk\WyudHn0[ZIu[my3ZTDhd5NigSxiSVO1NF0xNjB2OTFOwG0v M2H0UlIzPTh{OUmx
human A549 cell MlXSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIHiXodKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20PU43PiCwTR?= Mk\pV2FPT0WU
human NCI-H1703 cell NFXjTJVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV;UNJdjUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4ODNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12OT64NUBvVQ>? MXzTRW5ITVJ?
L1210 cell lines MUHGeY5kfGmxbjDhd5NigQ>? M1njb2NwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDDy[ZBtcWOjdHnvckBw\iCOMUKxNEBk\WyuIHzpcoV{KGK7IEWwKUBi\nSncjC3NkBpeiCrbnP1ZoF1cW:wLDDFSFUxRTBwMEWg{txONg>? MVWxOlUzODJ2
human K562 cells MmL5R5l1d3SxeHnjxsBie3OjeR?= M3PVUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMEWg{txO M3fJVVI1QTV4NUW2
human LB2241-RCC cell M1rlV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUXFXI5GUW6qaXLpeIlwdiCxZjDoeY1idiCOQkKyOFEuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUWuN|Qhdk1? M1nQZXNCVkeHUh?=
human MLMA cell NUDIVFVUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHr0fHdKdmirYnn0bY9vKG:oIHj1cYFvKE2OTVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21OU42OSCwTR?= M1vDcHNCVkeHUh?=
human P30-OHK cell MnjsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXfH[XdMUW6qaXLpeIlwdiCxZjDoeY1idiCSM{CtU2hMKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PTZwNTDuUS=> NUXIeW1TW0GQR1XS
RPMI-6410 human leukemic lymphoblastoid cell lines NUfoUmM6S3m2b4TvfIlkyqCjc4PhfS=> NVTvc|RsS3m2b4TvfIlkcXS7IHHnZYlve3RiUmDNTU03PDFyIHj1cYFvKGyndXvlcYlkKGy7bYDoc4Jt[XO2b3nkJINmdGxibHnu[ZMtKEmFNUC9NE4xPiEQvF2= MkDSOlgzPzV2Nh?=
human HT-29 cells NUjZfI84WHKxbHnm[ZJifGmxbjDhd5NigQ>? NH;DSYlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wOlYh|ryPLh?= MVGyO|c5PDR7
human NCI-H510A cell NY\4SHI5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlXvTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEWxNGEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03QC5{NjDuUS=> NFTHSodUSU6JRWK=
human J-RT3-T3-5 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIn2endKdmirYnn0bY9vKG:oIHj1cYFvKEpvUmSzMXQ{NTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14OD60NkBvVQ>? M3q0d3NCVkeHUh?=
human VA-ES-BJ cell M3zVPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGjtOZlKdmirYnn0bY9vKG:oIHj1cYFvKF[DLVXTMWJLKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PzFwNkWgcm0> M4\Ge3NCVkeHUh?=
human T-24 cell M{XLUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIHR[2JKdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23PE42PiCwTR?= NGi4elBUSU6JRWK=
human NB69 cell NEDMfFdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVvTc2N7UW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|kvPDhibl2= NYjNSItVW0GQR1XS
human BALL-1 cells MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUfJWWhWOjRiaB?= NWDWTGtOT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSkGOTD2xJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCZU2StNUBie3OjeTygS2k2OD1yLkC4JO69VQ>? NIHTWoozOjJ4NEG3NC=>
HL60 cells M2jieXBzd2yrZnXyZZRqd25iYYPzZZk> Mn7JTY4hfmm2cn:gbY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RicILvcIln\XKjdHnvckBw\iCKTE[wJINmdGy|LDDJR|UxRTBwMEig{txO M4SxZ|EzQDd5NUmz
human CTV-1 cell M12yW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkjBTY5pcWKrdHnvckBw\iCqdX3hckBEXFZvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUi0Mlc1KG6P MV7TRW5ITVJ?
human MEL-JUSO cell NWi5SoliT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2rkXmlvcGmkaYTpc44hd2ZiaIXtZY4hVUWOLVrVV28h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05PS55NjDuUS=> MUjTRW5ITVJ?
human MOLT-4 cell MlXQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWe5[I9ZUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05QS54NzDuUS=> M4DUPXNCVkeHUh?=
human leukemia cell line(CCRF-CEM) NIXmSHJEgXSxdH;4bYPDqGG|c3H5 NIrlO|dKdiC4aYTyc{BkgXSxdH;4bYNqfHlib3[gZ49ueG:3bnTzJJdmemViZHX0[ZJucW6nZDDvckBKdmirYnn0bY9vKG:oIHj1cYFvKGyndXvlcYliKGOnbHygcIlv\SiFQ2LGMWNGVSluIFnDOVA:OC5yOTFOwG0v MXG4PVE4PjR3
human SW982 cell MnuzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmTjTY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmxMlI{KG6P MorDV2FPT0WU
human NCI-SNU-1 cell NUW3OnNOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYnPXo14UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtV25WNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3Ojef-8kEBKSzVyPUm2Mlc4KG6P Ml3XV2FPT0WU
HeLa human cell lines NXjncoozTnWwY4Tpc44h[XO|YYm= MUKxOFQhcA>? NWfFZmpkXGinIHPvcZBwfW6mIIfhd{B1\XO2ZXSgbY4hfmm2cn:g[o9zKGGwdHn0eY1weiCjY4Tpeol1gSh3MDWgbY5pcWKrdHnvckBw\iC2dX3vdkBk\WyuIHfyc5d1cCliYXfhbY5{fCCKZVzhJIh2dWGwIHPlcIwhdGmwZYOgZYZ1\XJiMUS0JIhzNCCLREWwQVAvOSEQvF2= M1r0[FM3OjV5MUS=
human H460 cells MUDGeY5kfGmxbjDhd5NigQ>? NHiwSoUzPCCq NE\W[mlCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYpCpC=> NUDENW03OjB{MUG1OlQ>
human HCT116 cells M1zuc2Z2dmO2aX;uJIF{e2G7 NVXseW5WSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4yKM7:TR?= NWfBbYFkOjB{MUG1OlQ>
human GP5d cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkHmTY5pcWKrdHnvckBw\iCqdX3hckBIWDWmIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUCyJI5O M4XvbnNCVkeHUh?=
human SAS cell M3\6[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnfBTY5pcWKrdHnvckBw\iCqdX3hckBUSVNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMEeuOVchdk1? M3;JdnNCVkeHUh?=
human BFTC-905 cell  NYLtRo44T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmTBTY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExQC5|MTDuUS=> MV;TRW5ITVJ?
human LB1047-RCC cell NWTldW5UT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnfPTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTB6LkSyJI5O Mli1V2FPT0WU
human BB65-RCC cell NWHOO5hCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGJDPjVvUlPDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVExNjF7IH7N MWXTRW5ITVJ?
human KE-37 cell M{C1dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWLJcohq[mm2aX;uJI9nKGi3bXHuJGtGNTN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUGwMlg2KG6P MX;TRW5ITVJ?
human NCI-H292 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXPOOYlyUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzND6yJI5O MoPlV2FPT0WU
human HT-1080 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3vkSmlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyPC52NzDuUS=> M2XlSnNCVkeHUh?=
human HL60 cells M12yZWN6fG:2b4jpZ:Kh[XO|YYm= MWO0PEBp NXy3WlNjS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOTF6IN88US=> MYmxPVMzOTJ|NB?=
human CAKI-1 cell MmHuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkHZS5Jwf3SqIHnubIljcXSrb36gc4Yh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JHdUXC1zIHHzd4F6NCCJSUWwQVAvOTJizszN NGHZT|MzOjJ4NEG3NC=>
human CAKI-1 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlSxTY5pcWKrdHnvckBw\iCqdX3hckBESUuLLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNlAhdk1? MonqV2FPT0WU
human HMV-II cell NEnGSYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmjjTY5pcWKrdHnvckBw\iCqdX3hckBJVVZvSVmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfS=> M{[5XXNCVkeHUh?=
human ES8 cell Ml\JS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkHPTY5pcWKrdHnvckBw\iCqdX3hckBGWzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMkOuPVMhdk1? NFu2eFJUSU6JRWK=
human NEC8 cell NWS1NWtjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYjJcohq[mm2aX;uJI9nKGi3bXHuJG5GSzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zM{SuNlEhdk1? NWXjV29TW0GQR1XS
human EW-1 cell NX3KcI5kT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn;rTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUO4MlYzKG6P NXv2[HFzW0GQR1XS
murine leukemia P388 MYTGeY5kfGmxbjDhd5NigQ>? MUTBcpRq[2GwY3XyJIFkfGm4aYT5JINienKrZXSgc5V1KGmwII\peJJwKGGpYXnud5QhdXW{aX7lJIxmfWunbXnhJHA{QDhuIFnDOVA:OC5zNDFOwG0> NWr2OYFEOTF|NU[xNVA>
human H-EMC-SS cell NIL3dpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHzEPYtKdmirYnn0bY9vKG:oIHj1cYFvKEhvRV3DMXNUKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTR3LkK4JI5O M3PhUnNCVkeHUh?=
human SNU638 cells M4\jO2N6fG:2b4jpZ:Kh[XO|YYm= M4XkSmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNPXTZ|ODDj[YxteyCkeTDTVmIh[XO|YYmsJGlEPTB;MD6xOUDPxE1? MVKyOFk2PjV3Nh?=
human COR-L105 cell M3\TeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYTJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYxNjN7IH7N NFX0PWtUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Cytarabine is highly effective against acute leukaemias, which causes the characteristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man. [4] Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity. [5]

Protocol

Kinase Assay:[1]
+ Expand

In Vitro Growth Inhibition Assay:

Stock solution of Cytarabine is prepared in absolute ethanol, and serial dilutions of Cytarabine are prepared. CCRF-CEM cells are suspended in RPMI medium supplemented with 10% FBS, 0.1% gentamicin, and 1% sodium pyruvate. The cells are suspended in their respective media to give 10 mL volumes of cell suspension at a final density of 3-6 × 104 cells/mL. Appropriate volumes of Cytarabine solution are transferred to the cell suspensions, and incubation is continued for 72 hours. The cells are spun down and resuspended in fresh Cytarabine -free medium, and final cell counts are determined. The data are analyzed by sigmoidal curve fitting of the cell count versus Cytarabine concentration, and the results are expressed as the IC50 (Cytarabine concentration that inhibits cell growth to 50% of the control value).
Cell Research:[2]
+ Expand
  • Cell lines: Rat leukemic cell lines RCL/0, RO/1 and K7 and human myelomonocytic leukemic U937
  • Concentrations: ~100 μM
  • Incubation Time: 24, 48 and 72 hours
  • Method: Cells are incubated in the presence of different concentrations of Cytarabine at 37 °C for 24, 48, and 72 hours. At the time of 20-, 44-, or 68-hour incubation in the presence of Cytarabine, 10 mL of cell proliferation reagent WST-1 solution is added. After 2- and 4-hour incubation with WST-1, cell metabolic activity is assessed with colorimetric changes quantified by measuring the absorbance in a spectrophotometer at 450 nm. And cell division times are calculated from eosin counting in parallel with viability assay
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Brown Norway rat with myelocytic leukaemia
  • Formulation: Dissolved in phosphate-buffered saline (pH 7.0) just before use.
  • Dosages: 5 - 1000 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro Water 48 mg/mL (197.35 mM)
DMSO 1 mg/mL (4.11 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
Saline
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 243.22
Formula

C9H13N3O5

CAS No. 147-94-4
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02756962 Recruiting Acute Myeloid Leukemia Washington University School of Medicine July 6, 2016 Phase 2
NCT01555268 Completed Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia Roswell Park Cancer Institute|National Cancer Institute (NCI)|Amgen October 31, 2011 Phase 1
NCT02203526 Suspended Primary Central Nervious System Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 24, 2014 Phase 1
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT02483000 Not yet recruiting Adult Burkitt Lymphoma|Adult Diffuse Large B-Cell Lymphoma|CD20-Positive Neoplastic Cells Present|Indolent Adult Non-Hodgkin Lymphoma|Mantle Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Refractory Mature B-Cell Non-Hodgkin Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) March 2017 Phase 1
NCT03019640 Not yet recruiting B-Cell Non-Hodgkin Lymphoma M.D. Anderson Cancer Center March 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Cytarabine | Cytarabine supplier | purchase Cytarabine | Cytarabine cost | Cytarabine manufacturer | order Cytarabine | Cytarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID